Antibodies against HLA-E–VL9 enhance NK cell and CD8+ T cell cytotoxicity against tumor cells and HIV-infected CD4+ T cells | Science Translational Medicine
HLA-E–VL9 antibodies enhance NK cell and CD8+ T cell killing of tumor cells and HIV-infected cells.
